A Better Way to Better Medicine
We are building a portfolio of compounds that have first-in-class and best-in-class potential through our own discovery research and clinical development initiatives.
more >

News
11/18/09 Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference

11/17/09 Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference

Exelixis at EORTC 2009
Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference.
more >

Exelixis at SNO 2009
One abstract featuring Exelixis' XL184 was presented at the meeting from October 22-24, 2009.
more >

Investor Webcasts
12/01/2009 - 01:30 PM Exelixis at Piper Jaffray Healthcare Conference

Careers
Looking for a career at Exelixis? We are looking for people to join us as we turn our vision into reality.
more >

Stock
NASDAQ: EXEL
Nov 20 2009 4:00PM
PRICE: 6.71 +0.08
VOLUME: 1137820 SHARES
20 minute delay
more >